{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:00:58Z","timestamp":1793145658012,"version":"4.5.0"},"reference-count":64,"publisher":"Academy of Medicine, Singapore","issue":"5","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Acad Med Singap"],"abstract":"<jats:p>Introduction: Osteoporosis is a progressive disease characterised by changes in bone structure leading to fragility fractures. In Singapore, it is a significant health concern with a high prevalence, and is expected to increase as the population ages. These consensus statements aim to provide scientifically grounded recommendations for the management of osteoporosis, to standardise its management in Singapore and promote multidisciplinary collaboration.\nMethods: An expert panel comprising 18 representatives from 10 Singapore medical bodies developed consensus statements based on current evidence and through multiple online meetings. Each panellist voted on each statement independently using a 3-point Likert scale (Agree, Neutral, Disagree). Consensus (total ratings of \u201cAgree\u201d) was set a priori at \u226580%, with statements not reaching this threshold excluded for lacking consensus. \nResults: The expert panel reached consensus on 80 consensus statements. These include 10 statements on screening, risk factors, and fracture risk assessment; 7 statements on initial bone mineral density testing; 5 on the indications for pharmacotherapy; 20 on osteoporosis pharmacotherapy; 24 on treatment targets, treatment monitoring, and follow-up bone mineral density testing; and 14 statements on the prevention and management of medication-related osteonecrosis of the jaw.\nConclusion: The consensus statements in this paper guide clinicians in using the latest evidence and expert opinion to inform appropriate diagnostic and therapeutic approaches for the management of osteoporosis. These statements are not intended to replace current guidelines, but rather to support clinical decision-making and help develop individualised, patient-centred management plans based on the patient\u2019s demographics, clinical characteristics, and preferences.<\/jats:p>","DOI":"10.47102\/annals-acadmedsg.202658","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:38:05Z","timestamp":1779266285000},"page":"252","source":"Crossref","is-referenced-by-count":2,"title":["2025 Singapore consensus statements on the management of osteoporosis"],"prefix":"10.47102","volume":"55","author":[{"given":"Linsey","family":"Gani","sequence":"first","affiliation":[{"name":"LG Endocrinology, Novena Medical Center, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siok Bee","family":"Chionh","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-205X","authenticated-orcid":false,"given":"Nur Azizah","family":"Allameen","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Division of Medicine, Woodlands Health, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Jiahui","family":"Chan","sequence":"additional","affiliation":[{"name":"Cancer Rehabilitative Services, Singapore Cancer Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Chandran","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Osteoporosis & Bone Metabolism Unit, Singapore General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Chew","sequence":"additional","affiliation":[{"name":"Excel Dental, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3334-4312","authenticated-orcid":false,"given":"Ivan","family":"Chua","sequence":"additional","affiliation":[{"name":"Orthopaedics International, Mount Elizabeth Novena Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swee Sen","family":"Foo","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Sengkang General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intekhab","family":"Islam","sequence":"additional","affiliation":[{"name":"Oral & Maxillofacial Surgery, National University Centre for Oral Health Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1810-0926","authenticated-orcid":false,"given":"Tang","family":"Ching Lau","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Lim","sequence":"additional","affiliation":[{"name":"Gleneagles Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Yi","family":"Lim","sequence":"additional","affiliation":[{"name":"Endodontic Unit, Restorative Dentistry, National Dental Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Ng","sequence":"additional","affiliation":[{"name":"The Endocrine Clinic, Mount Elizabeth Medical Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Ramason","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donovan","family":"Tay","sequence":"additional","affiliation":[{"name":"Arden Diabetes and Endocrine Clinic, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-4676","authenticated-orcid":false,"given":"Jason Shau Khng","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynaecology, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6511-770X","authenticated-orcid":false,"given":"Eu-Leong","family":"Yong","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-634X","authenticated-orcid":false,"given":"Seng Bin","family":"Ang","sequence":"additional","affiliation":[{"name":"Family Medicine Service and Menopause Centre, KK Women\u2019s and Children\u2019s Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26165","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Chandran M, Brind\u2019Amour K, Fujiwara S, et al. Prevalence of osteoporosis and incidence of related fractures in developed economies in the Asia Pacific region: a systematic review. Osteoporosis Int 2023;34:1037-53. DOI: 10.1007\/s00198-022-06657-8","DOI":"10.1007\/s00198-022-06657-8"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Cheung CL, Ang SB, Chadha M, et al. An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study. Osteoporos Sarcopenia 2018;4:16-21. DOI: 10.1016\/j.afos.2018.03.003","DOI":"10.1016\/j.afos.2018.03.003"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Yong EL, Ganesan G, Kramer MS, et al. Hip fractures in Singapore: ethnic differences and temporal trends in the new millennium. Osteoporosis Int 2019;30:879-86. DOI: 10.1007\/s00198-019-04839-5","DOI":"10.1007\/s00198-019-04839-5"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Yong EL, Ganesan G, Kramer MS, et al. Risk Factors and Trends Associated With Mortality Among Adults With Hip Fracture in Singapore. JAMA Netw Open 2020;3:e1919706. DOI: 10.1001\/jamanetworkopen.2019.19706","DOI":"10.1001\/jamanetworkopen.2019.19706"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Yong EL, Logan S. Menopausal osteoporosis: screening, prevention and treatment. Singapore Med J 2021;62:159-66. DOI: 10.11622\/smedj.2021036","DOI":"10.11622\/smedj.2021036"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Lim VW, Li J, Gong Y, et al. Serum free estradiol and estrogen receptor-\u03b1 mediated activity are related to decreased incident hip fractures in older women. Bone 2012;50:1311-6. DOI: 10.1016\/j.bone.2012.03.006","DOI":"10.1016\/j.bone.2012.03.006"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Thu WPP, Logan SJS, Cauley JA, et al. Ethnic differences in bone mineral density among midlife women in a multi-ethnic Southeast Asian cohort. Arch Osteoporos 2019;14:80. DOI: 10.1007\/s11657-019-0631-0","DOI":"10.1007\/s11657-019-0631-0"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Tng HY, Thu WPP, Logan S, et al. Sleep apnea and femoral neck BMD among Singaporean mid-life women. Arch Osteoporos 2018;13:19. DOI: 10.1007\/s11657-018-0428-6","DOI":"10.1007\/s11657-018-0428-6"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Logan S, Thu WPP, Lay WK, et al. Chronic joint pain and handgrip strength correlates with osteoporosis in mid-life women: a Singaporean cohort. Osteoporos Int 2017;28:2633-43. DOI: 10.1007\/s00198-017-4095-z","DOI":"10.1007\/s00198-017-4095-z"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Yong EL, Wong BWX, Tan DYZ. Beyond BMI: The Janus-like effect of muscle versus fat on midlife women\u2019s health. Ann Acad Med Singap 2025;54:125-8. DOI: 10.47102\/annals-acadmedsg.2024278","DOI":"10.47102\/annals-acadmedsg.2024278"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Choong DS, Tan NC, Koh YLE, et al. Osteoporosis management by primary care physicians in Singapore: a survey on osteoporosis guidelines utilisation and barriers to care. Arch Osteoporos 2023;18:72. Erratum in: Arch Osteoporos 2023 21;18:84. DOI: 10.1007\/s11657-023-01283-1","DOI":"10.1007\/s11657-023-01283-1"},{"key":"ref11","unstructured":"12. Agency for Care Effectiveness (ACE). Osteoporosis: diagnosis and management. ACE Clinical Guidance (ACG), Ministry of Health, Singapore, 2025. go.gov.sg\/acg-osteoporosis. Accessed 15 August 2025."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Balshem H, Helfand M, Sch\u00fcnemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. DOI: 10.1016\/j.jclinepi.2010.07.015","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Hasson F, Keeney S, McKenna H. Revisiting the Delphi technique - Research thinking and practice: A discussion paper. Int J Nurs Stud 2025;168:105119. DOI: 10.1016\/j.ijnurstu.2025.105119","DOI":"10.1016\/j.ijnurstu.2025.105119"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Koh LK, Sedrine WB, Torralba TP, et al. A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 2001;12:699-705. DOI: 10.1007\/s001980170070","DOI":"10.1007\/s001980170070"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Fan Z, Li X, Zhang X, et al. Comparison of OSTA, FRAX and BMI for Predicting Postmenopausal Osteoporosis in a Han Population in Beijing: A Cross Sectional Study. Clin Interv Aging 2020;15:1171-80. DOI: 10.2147\/CIA.S257166","DOI":"10.2147\/CIA.S257166"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Cherian KE, Kapoor N, Shetty S, et al. Evaluation of Different Screening Tools for Predicting Femoral Neck Osteoporosis in Rural South Indian Postmenopausal Women. J Clin Densitom 2018;21:119-24. DOI: 10.1016\/j.jocd.2017.08.002","DOI":"10.1016\/j.jocd.2017.08.002"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Nayak S, Edwards DL, Saleh AA, et al. Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density. Osteoporos Int 2015;26:1543-54. DOI: 10.1007\/s00198-015-3025-1","DOI":"10.1007\/s00198-015-3025-1"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Cheung CL, Li GH, Li HL, et al. Development and validation of the Chinese osteoporosis screening algorithm (COSA) in identification of people with high risk of osteoporosis. Osteoporos Sarcopenia 2023;9:8-13. DOI: 10.1016\/j.afos.2023.03.009","DOI":"10.1016\/j.afos.2023.03.009"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20. Chandran M, Chin YA, Choo KS, et al. Comparison of the Osteoporosis Self-Assessment Tool for Asians and the fracture risk assessment tool - FRAX to identify densitometric defined osteoporosis: A discriminatory value analysis in a multi-ethnic female population in Southeast Asia. Osteoporos Sarcopenia 2020;6:53-8. DOI: 10.1016\/j.afos.2020.04.001","DOI":"10.1016\/j.afos.2020.04.001"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Kanis JA, Chandran M, Chionh SB, et al. Use of age-dependent FRAX-based intervention thresholds for Singapore. Arch Osteoporos 2020;15:104. DOI: 10.1007\/s11657-020-00782-9","DOI":"10.1007\/s11657-020-00782-9"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Yong EL, Ganesan G, Kramer MS, et al. Hip fractures in Singapore: ethnic differences and temporal trends in the new millennium. Osteoporos Int 2019;30:879-86. DOI: 10.1007\/s00198-019-04839-5","DOI":"10.1007\/s00198-019-04839-5"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 2018;391:741-7. DOI: 10.1016\/S0140-6736(17)32640-5","DOI":"10.1016\/S0140-6736(17)32640-5"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24. Wong P, Chen W, Ewald D, et al. 2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age. Med J Australia 2025;222:472-80. DOI: 10.5694\/mja2.52637","DOI":"10.5694\/mja2.52637"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25. Chandran M, Ganesan G, Tan KB, et al. Cost-effectiveness of FRAX\u00ae-based intervention thresholds for management of osteoporosis in Singaporean women. Osteoporos Int 2021;32:133-44. DOI: 10.1007\/s00198-020-05536-4","DOI":"10.1007\/s00198-020-05536-4"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis\u2014 2020 Update Executive Summary. Endocrine Practice 2020;26:564-70. DOI: 10.4158\/GL-2020-0524","DOI":"10.4158\/GL-2020-0524"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27. Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2018;30:3-44. DOI: 10.1007\/s00198-018-4704-5","DOI":"10.1007\/s00198-018-4704-5"},{"key":"ref27","unstructured":"28. International Society of Clinical Densitometry. 2023 ISCD Official Positions Adult. https:\/\/iscd.org\/official-positions-2023\/. Accessed 2 July 2025."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Yong EL, Logan S. Menopausal osteoporosis: screening, prevention and treatment. Singapore Med J 2021;62:159-66. DOI: 10.11622\/smedj.2021036","DOI":"10.11622\/smedj.2021036"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30. Huang CF, Ho CJ, Lin SY, et al. Asia-Pacific consensus for the management of osteoporosis in men. Osteoporos Int Jul 2025;36:1105-14. DOI: 10.1007\/s00198-025-07559-1","DOI":"10.1007\/s00198-025-07559-1"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767-94. DOI: 10.1097\/GME.0000000000002028","DOI":"10.1097\/GME.0000000000002028"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32. Ang SB, Sugianto SRS, Tan FCJH, et al. Asia-Pacific Menopause Federation Consensus Statement on the Management of Menopause 2024. J Menopausal Med 2025;31:3. DOI: 10.6118\/jmm.25104","DOI":"10.6118\/jmm.25104"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33. de Villiers TJ, Goldstein SR. Update on bone health: the International Menopause Society White Paper 2021. Climacteric 2021;24:498-504. DOI: 10.1080\/13697137.2021.1950967","DOI":"10.1080\/13697137.2021.1950967"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34. Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2016;10:CD008536. DOI: 10.1002\/14651858.CD008536.pub3","DOI":"10.1002\/14651858.CD008536.pub3"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35. Lorentzon M, Johansson H, Harvey NC, et al. Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability\u2014results from the Women\u2019s Health Initiative hormone therapy trials. Osteoporos Int 2022;33(:2297-305. DOI: 10.1007\/s00198-022-06483-y","DOI":"10.1007\/s00198-022-06483-y"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 2022;33:2049-102. DOI: 10.1007\/s00198-021-05900-y","DOI":"10.1007\/s00198-021-05900-y"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41. Erratum in: JAMA 2006;296:2926. Erratum in: JAMA 2007 5;298:973. DOI: 10.1001\/jama.295.23.joc60074","DOI":"10.1001\/jama.295.23.joc60074"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene. J Natl Cancer Inst 2004;96:1751-61. DOI: 10.1093\/jnci\/djh319","DOI":"10.1093\/jnci\/djh319"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39. MacLean C, Newberry S, Maglione M, et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. Ann Intern Med 2008;148:197-213. DOI: 10.7326\/0003-4819-148-3-200802050-00198","DOI":"10.7326\/0003-4819-148-3-200802050-00198"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40. Tai TW, Chen HY, Shih CA, et al. Asia-Pacific consensus on long-term and sequential therapy for osteoporosis. Osteoporos Sarcopenia 2024;10:3-10. DOI: 10.1016\/j.afos.2024.02.001","DOI":"10.1016\/j.afos.2024.02.001"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41. Black DM, Geiger EJ, Eastell R, et al. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med 2020;383:743-53. DOI: 10.1056\/NEJMoa1916525","DOI":"10.1056\/NEJMoa1916525"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42. Gani L, Anthony N, Dacay L, et al. Incidence of Atypical Femoral Fracture and Its Mortality in a Single Center in Singapore. JBMR Plus 2021;5:e10515. DOI: 10.1002\/jbm4.10515","DOI":"10.1002\/jbm4.10515"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43. Nguyen HH, Lakhani A, Shore-Lorenti C, et al. Asian ethnicity is associated with atypical femur fractures in an Australian population study. Bone 2020;135:115319. DOI: 10.1016\/j.bone.2020.115319","DOI":"10.1016\/j.bone.2020.115319"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44. Davis S, Simpson E, Hamilton J, et al. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol Assess 2020;24:1-314. DOI: 10.3310\/hta24290","DOI":"10.3310\/hta24290"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45. Bone HG, Bolognese MA, Yuen CK, et al. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women. J Clin Endocrinol Metab 2008;93:2149-57. DOI: 10.1210\/jc.2007-2814","DOI":"10.1210\/jc.2007-2814"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46. Lamy O, Everts-Graber J, Rodriguez EG. Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach. Aging Clin Exp Res 2025;37:70. DOI: 10.1007\/s40520-025-02991-z","DOI":"10.1007\/s40520-025-02991-z"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47. Kumar S, Wang M, Kim AS, et al. Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. J Bone Miner Res 2025;40:1017-34. DOI: 10.1093\/jbmr\/zjaf037","DOI":"10.1093\/jbmr\/zjaf037"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48. Tay WL, Tay D. Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature. Endocrinol Metab (Seoul) 2022;37:183-194. DOI: 10.3803\/EnM.2021.1369","DOI":"10.3803\/EnM.2021.1369"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016;375:1532-43. DOI: 10.1056\/NEJMoa1607948","DOI":"10.1056\/NEJMoa1607948"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50. Park JY, Park HM, Song JY, et al. Real-World Evaluation of 12-Month Romosozumab Treatment in Korean Women with Severe Osteoporosis: Potential Synergy with Hormone Therapy. J Clin Med 2025;14:2958. DOI: 10.3390\/jcm14092958","DOI":"10.3390\/jcm14092958"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51. Cosman F, Lewiecki EM, Eastell R, et al. Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res 2024;39:1393-405. DOI: 10.1093\/jbmr\/zjae119","DOI":"10.1093\/jbmr\/zjae119"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52. Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 2019;31:1-12. DOI: 10.1007\/s00198-019-05176-3","DOI":"10.1007\/s00198-019-05176-3"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53. Black DM, Rosen CJ. Postmenopausal Osteoporosis. N Engl J Med 2016;374:254-62. DOI: 10.1056\/NEJMcp1513724","DOI":"10.1056\/NEJMcp1513724"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2019;104:1595-622. DOI: 10.1210\/jc.2019-00221","DOI":"10.1210\/jc.2019-00221"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015;386:1147-55. DOI: 10.1016\/S0140-6736(15)61120-5","DOI":"10.1016\/S0140-6736(15)61120-5"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56. Cummings SR, Ferrari S, Eastell R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res 2017;33:190-8. DOI: 10.1002\/jbmr.3337","DOI":"10.1002\/jbmr.3337"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57. Gani LU, Sritara C, Blank RD, et al. Follow-up Bone Mineral Density Testing: 2023 Official Positions of the International Society for Clinical Densitometry. J Clin Densitom 2024;27:101440. DOI: 10.1016\/j.jocd.2023.101440","DOI":"10.1016\/j.jocd.2023.101440"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58. Vasikaran S, Eastell R, Bruy\u00e8re O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2010;22:391-420. DOI: 10.1007\/s00198-010-1501-1","DOI":"10.1007\/s00198-010-1501-1"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59. Shane E, Burr D, Abrahamsen B, et al. Atypical subtronchanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29:1-23. DOI: 10.1002\/jbmr.1998","DOI":"10.1002\/jbmr.1998"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60. Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws\u20142022 Update. J Oral Maxillofac Surg 2022;80:920-43. DOI: 10.1016\/j.joms.2022.02.008","DOI":"10.1016\/j.joms.2022.02.008"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61. Dodson TB. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors. Oral Maxillofac Surg Clin North Am 2015;27:509-16. DOI: 10.1016\/j.coms.2015.06.003","DOI":"10.1016\/j.coms.2015.06.003"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62. Aboalela AA, Farook FF, Alqahtani AS, et al. The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis. Cureus 2022;14:e30485. DOI: 10.7759\/cureus.30485","DOI":"10.7759\/cureus.30485"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63. Ruksakiet K, Jarusriwanna A, Sadaeng W, et al. Effects of discontinuing different antiresorptive regimens on medication-related osteonecrosis of the jaw in patients undergoing dental procedures: a systematic review and network meta-analysis. EFORT Open Rev 2025;10:258-66. DOI: 10.1530\/EOR-2024-0133","DOI":"10.1530\/EOR-2024-0133"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64. Patel N, Seoudi N. Management of Medication-Related Osteonecrosis of the Jaw: An Overview of National and International Guidelines. Br J Oral Maxillofac Surg 2024;62:899-908. DOI: 10.1016\/j.bjoms.2024.08.008","DOI":"10.1016\/j.bjoms.2024.08.008"}],"container-title":["Annals of the Academy of Medicine Singapore"],"original-title":[],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:27:10Z","timestamp":1780032430000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals.edu.sg\/2025-singapore-consensus-statements-management-osteoporosis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,29]]}},"URL":"https:\/\/doi.org\/10.47102\/annals-acadmedsg.202658","relation":{},"ISSN":["2972-4066"],"issn-type":[{"value":"2972-4066","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}